Figure 4.

The ERK1/2 pathway may be involved in scutellarin-induced NSC proliferation

(A) NSCs were treated with vehicle, scutellarin (SCU) or the combination of scutellarin and ERK1/1 inhibitor U0126 (S+U). Lysates were blotted using antibodies against total ERK1/2 (T-ERK1/2) or phospho-ERK1/2 (P-ERK1/2)

(B) Quantitative analysis of Western blots like that in panel A (n=3 per group). SCU increased the ratio of P-ERK1/2 to T-ERK1/2, which U0126 attenuated. *P<0.05 vs vehicle; #P<0.05 vs scutellarin

(C) NSCs were stained with antibodies against BrdU and nestin.

(D) Quantitative analysis of NSC proliferation (n=3 per group) **P<0.01 vs vehicle; #P<0.05 vs SCU